The Premier Buying Network for Medical Spas & Aesthetic Physicians


  Contact : 1.844.799.2384

Meet ESKATA™ by Aclaris

Members have access to an exclusive 15% quarterly rebate on all ESKATA purchases! Contact us today to get more information about how you can introduce ESKATA to your practice!

*Members who are already receiving national contract pricing will not be eligible for the MRN quarterly rebate program.

CONTACT US FOR ESKATA

Fill out our form below and someone from ESKATA will connect with you shortly.
  • This field is for validation purposes and should be left unchanged.

INDICATIONS AND USAGE

ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) is indicated for the treatment of seborrheic keratoses that are raised.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Do not apply ESKATA to the eyes or mucous membranes. Avoid treating seborrheic keratoses within the orbital rim. Direct contact with the eye can cause corneal injury (erosion, ulceration, perforation, and scarring), chemical conjunctivitis, eyelid edema, severe eye pain or permanent eye injury, including blindness. If accidental exposure occurs, flush with water for 15 to 30 minutes, initiate monitoring and further evaluation as appropriate.

Skin reactions occurred in the treatment area after application of ESKATA. Severe local skin reactions included erosion, ulceration, vesiculation and scarring. Do not retreat until the skin has recovered from any reaction caused by the previous treatment.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions include erythema (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and pruritus (58%).

CONTRAINDICATIONS

None.

DOSAGE AND ADMINISTRATION

ESKATA is to be administered by a healthcare provider. For topical use only. Not for oral, ophthalmic, or intravaginal use. Not for open or infected seborrheic keratoses.

Please see accompanying full Prescribing Information for ESKATA (hydrogen peroxide) topical solution, 40% (w/w).

Reference: 1. Data on file. Aclaris Therapeutics, Inc. 2018.

Pin It on Pinterest